Bicara Therapeutics Inc. Common StockBCAX
About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
229% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 7
75% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]
63% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 24
22% more funds holding
Funds holding: 68 [Q3] → 83 (+15) [Q4]
19.0% more ownership
Funds ownership: 66.83% [Q3] → 85.82% (+19.0%) [Q4]
12% less capital invested
Capital invested by funds: $926M [Q3] → $814M (-$112M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Cantor Fitzgerald Eric Schmidt 4% 1-year accuracy 1 / 26 met price target | 23%upside $13.01 | Overweight Reiterated | 13 Mar 2025 |
Wedbush David Nierengarten 34% 1-year accuracy 39 / 116 met price target | 193%upside $31 | Outperform Reiterated | 12 Feb 2025 |
HC Wainwright & Co. Robert Burns 15% 1-year accuracy 25 / 172 met price target | 326%upside $45 | Buy Maintained | 27 Jan 2025 |
Financial journalist opinion









